Logo image of IPA

IMMUNOPRECISE ANTIBODIES LTD (IPA) Stock Fundamental Analysis

NASDAQ:IPA - CA45257F2008 - Common Stock

2.76 USD
-0.44 (-13.75%)
Last: 8/25/2025, 8:00:02 PM
2.8 USD
+0.04 (+1.45%)
After Hours: 8/25/2025, 8:00:02 PM
Fundamental Rating

2

IPA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 54 industry peers in the Life Sciences Tools & Services industry. The financial health of IPA is average, but there are quite some concerns on its profitability. IPA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IPA had negative earnings in the past year.
In the past year IPA has reported a negative cash flow from operations.
In the past 5 years IPA always reported negative net income.
In the past 5 years IPA always reported negative operating cash flow.
IPA Yearly Net Income VS EBIT VS OCF VS FCFIPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

The Return On Assets of IPA (-101.28%) is worse than 90.74% of its industry peers.
IPA's Return On Equity of -183.56% is on the low side compared to the rest of the industry. IPA is outperformed by 87.04% of its industry peers.
Industry RankSector Rank
ROA -101.28%
ROE -183.56%
ROIC N/A
ROA(3y)-32.43%
ROA(5y)-25.28%
ROE(3y)-49.42%
ROE(5y)-38.79%
ROIC(3y)N/A
ROIC(5y)N/A
IPA Yearly ROA, ROE, ROICIPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 50.82%, IPA is in line with its industry, outperforming 57.41% of the companies in the same industry.
In the last couple of years the Gross Margin of IPA has remained more or less at the same level.
IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 50.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.62%
GM growth 5Y0.29%
IPA Yearly Profit, Operating, Gross MarginsIPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

4

2. Health

2.1 Basic Checks

IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for IPA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IPA Yearly Shares OutstandingIPA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
IPA Yearly Total Debt VS Total AssetsIPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

IPA has an Altman-Z score of 1.94. This is not the best score and indicates that IPA is in the grey zone with still only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 1.94, IPA perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
A Debt/Equity ratio of 0.45 indicates that IPA is not too dependend on debt financing.
The Debt to Equity ratio of IPA (0.45) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Altman-Z 1.94
ROIC/WACCN/A
WACC9.72%
IPA Yearly LT Debt VS Equity VS FCFIPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

IPA has a Current Ratio of 2.32. This indicates that IPA is financially healthy and has no problem in meeting its short term obligations.
IPA's Current ratio of 2.32 is in line compared to the rest of the industry. IPA outperforms 46.30% of its industry peers.
A Quick Ratio of 2.11 indicates that IPA has no problem at all paying its short term obligations.
IPA has a Quick ratio (2.11) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.32
Quick Ratio 2.11
IPA Yearly Current Assets VS Current LiabilitesIPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.78% over the past year.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.08%

3.2 Future

IPA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.31% yearly.
Based on estimates for the next years, IPA will show a quite strong growth in Revenue. The Revenue will grow by 18.02% on average per year.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.73%
Revenue Next 5Y18.02%

3.3 Evolution

IPA Yearly Revenue VS EstimatesIPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M
IPA Yearly EPS VS EstimatesIPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPA Price Earnings VS Forward Price EarningsIPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPA Per share dataIPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as IPA's earnings are expected to grow with 35.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%

More info and screens

0

5. Dividend

5.1 Amount

IPA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOPRECISE ANTIBODIES LTD

NASDAQ:IPA (8/25/2025, 8:00:02 PM)

After market: 2.8 +0.04 (+1.45%)

2.76

-0.44 (-13.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)07-29 2025-07-29/bmo
Earnings (Next)09-11 2025-09-11
Inst Owners8.61%
Inst Owner Change1.96%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap127.37M
Analysts80
Price Target5.1 (84.78%)
Short Float %1.67%
Short Ratio0.23
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.91%
Min EPS beat(2)6.2%
Max EPS beat(2)87.62%
EPS beat(4)3
Avg EPS beat(4)16.03%
Min EPS beat(4)-35.01%
Max EPS beat(4)87.62%
EPS beat(8)5
Avg EPS beat(8)11.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.67%
Min Revenue beat(2)-7.52%
Max Revenue beat(2)-5.81%
Revenue beat(4)0
Avg Revenue beat(4)-9.55%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)-2.06%
Revenue beat(8)3
Avg Revenue beat(8)-3.78%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.38
P/FCF N/A
P/OCF N/A
P/B 7.05
P/tB 10.99
EV/EBITDA N/A
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS0.37
BVpS0.39
TBVpS0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.28%
ROE -183.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 50.82%
FCFM N/A
ROA(3y)-32.43%
ROA(5y)-25.28%
ROE(3y)-49.42%
ROE(5y)-38.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.62%
GM growth 5Y0.29%
F-Score3
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.45
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 27.09%
Cap/Sales 6.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.32
Quick Ratio 2.11
Altman-Z 1.94
F-Score3
WACC9.72%
ROIC/WACCN/A
Cap/Depr(3y)25%
Cap/Depr(5y)25.27%
Cap/Sales(3y)6.15%
Cap/Sales(5y)5.92%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%8.08%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.73%
Revenue Next 5Y18.02%
EBIT growth 1Y13.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y53.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.18%
OCF growth 3YN/A
OCF growth 5YN/A